BIONTECH CEO Ugur Sahin Sells $7.2M in Shares Over Two Days
BioNTech chief executive and 10% owner Ugur Sahin sold 73,000 ordinary shares on 8 and 9 September, leaving him with 708,709 shares in the reported account.
BioNTech chief executive and 10% owner Ugur Sahin sold 73,000 ordinary shares on 8 and 9 September, leaving him with 708,709 shares in the reported account.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.